{"transactions":[{"id":914595,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-09T20:54:45.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026."}],"balance_after":125000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001628280-26-006624","document":"wk-form4_1770688482.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000162828026006624/wk-form4_1770688482.xml","form_type":"4"}},{"id":1238743,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-28T18:54:45.000Z","date":"2024-11-18","kind":"sale","planned":false,"acquired":false,"shares":43026,"price":4.99,"value":214699.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary transactions by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade."}],"balance_after":167522,"source":{"system":"sec-edgar","filing":"0001516551-25-000022","document":"wk-form4a_1740786879.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655125000022/wk-form4a_1740786879.xml","form_type":"4/A","original_submission_date":"2024-11-19"}},{"id":1238742,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-28T18:54:45.000Z","date":"2024-11-15","kind":"sale","planned":false,"acquired":false,"shares":190,"price":5.55,"value":1054.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary transactions by the Reporting Person."}],"balance_after":210548,"source":{"system":"sec-edgar","filing":"0001516551-25-000022","document":"wk-form4a_1740786879.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655125000022/wk-form4a_1740786879.xml","form_type":"4/A","original_submission_date":"2024-11-19"}},{"id":1243507,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T17:53:13.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the four year period beginning February 21, 2025."}],"balance_after":150000,"derivative":{"exercise_price":2.89,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001516551-25-000018","document":"wk-form4_1740610387.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655125000018/wk-form4_1740610387.xml","form_type":"4"}},{"id":1359534,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-11-19T21:57:12.000Z","date":"2024-11-18","kind":"sale","planned":false,"acquired":false,"shares":43206,"price":4.99,"value":215597.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary transactions by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade."}],"balance_after":166342,"source":{"system":"sec-edgar","filing":"0001516551-24-000117","document":"wk-form4_1732071425.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655124000117/wk-form4_1732071425.xml","form_type":"4"}},{"id":1359533,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-11-19T21:57:12.000Z","date":"2024-11-15","kind":"sale","planned":false,"acquired":false,"shares":190,"price":5.55,"value":1054.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary transactions by the Reporting Person."}],"balance_after":209548,"source":{"system":"sec-edgar","filing":"0001516551-24-000117","document":"wk-form4_1732071425.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655124000117/wk-form4_1732071425.xml","form_type":"4"}},{"id":1379461,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-30T20:32:26.000Z","date":"2024-10-28","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the four year period beginning October 28, 2024."}],"balance_after":125000,"derivative":{"exercise_price":5.15,"expiration_date":"2034-10-27","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001516551-24-000102","document":"wk-form4_1730334740.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655124000102/wk-form4_1730334740.xml","form_type":"4"}},{"id":1603586,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T06:15:02.000Z","date":"2024-02-29","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the four year period beginning February 29, 2024. Upon a change in control of the Issuer, 100% of the options will become fully vested."}],"balance_after":75000,"derivative":{"exercise_price":14.56,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001516551-24-000016","document":"wk-form4a_1709550894.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655124000016/wk-form4a_1709550894.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1603585,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-04T06:15:02.000Z","date":"2024-02-29","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests on the following milestones: 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest upon achieving a market cap of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the RSU's will become fully vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":209738,"source":{"system":"sec-edgar","filing":"0001516551-24-000016","document":"wk-form4a_1709550894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655124000016/wk-form4a_1709550894.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1607552,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-01T18:42:20.000Z","date":"2024-02-29","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the four year period beginning February 29, 2024. Upon a change in control of the Issuer, 100% of the options will become fully vested."}],"balance_after":75000,"derivative":{"exercise_price":14.56,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001516551-24-000012","document":"wk-form4_1709336528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655124000012/wk-form4_1709336528.xml","form_type":"4"}},{"id":1607551,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-01T18:42:20.000Z","date":"2024-02-29","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest at if the Company is acquired for total consideration of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the options will become fully vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":210738,"source":{"system":"sec-edgar","filing":"0001516551-24-000012","document":"wk-form4_1709336528.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655124000012/wk-form4_1709336528.xml","form_type":"4"}},{"id":1748795,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-06T20:29:59.000Z","date":"2023-11-06","kind":"grant","planned":false,"acquired":true,"shares":32053,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested."}],"balance_after":45436,"derivative":{"exercise_price":3.5,"expiration_date":"2033-08-25","underlying":"Common Stock","underlying_shares":32053},"source":{"system":"sec-edgar","filing":"0001516551-23-000096","document":"wk-form4_1699320590.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655123000096/wk-form4_1699320590.xml","form_type":"4"}},{"id":1748794,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-06T20:29:59.000Z","date":"2023-11-06","kind":"grant","planned":false,"acquired":true,"shares":128209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":185738,"source":{"system":"sec-edgar","filing":"0001516551-23-000096","document":"wk-form4_1699320590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655123000096/wk-form4_1699320590.xml","form_type":"4"}},{"id":1794362,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-29T18:53:11.000Z","date":"2023-08-25","kind":"grant","planned":false,"acquired":true,"shares":3345530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested."}],"balance_after":3345530,"derivative":{"exercise_price":0.014,"expiration_date":"2033-08-25","underlying":"Common Stock","underlying_shares":3345530},"source":{"system":"sec-edgar","filing":"0001516551-23-000064","document":"wk-form4_1693349578.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655123000064/wk-form4_1693349578.xml","form_type":"4"}},{"id":1794361,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-29T18:53:11.000Z","date":"2023-08-25","kind":"grant","planned":false,"acquired":true,"shares":13382118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":14382118,"source":{"system":"sec-edgar","filing":"0001516551-23-000064","document":"wk-form4_1693349578.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655123000064/wk-form4_1693349578.xml","form_type":"4"}},{"id":2470170,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"Arsenault Kaitlyn Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-16T18:59:38.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":1770000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests 25% on the one year anniversary of the grant date and 1/48th monthly thereafter. Upon a change in control of the Issuer, 100% of the options will become fully vested."}],"balance_after":1770000,"derivative":{"exercise_price":0.058,"expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":1770000},"source":{"system":"sec-edgar","filing":"0001516551-21-000027","document":"wf-form4_163969915831608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655121000027/wf-form4_163969915831608.xml","form_type":"4"}},{"id":2470169,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"Arsenault Kaitlyn Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-16T18:59:38.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests in three equal annual installments commencing on the first anniversary of the grant date. Upon a change in control of the Issuer, all of the RSUs will vest in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001516551-21-000027","document":"wf-form4_163969915831608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655121000027/wf-form4_163969915831608.xml","form_type":"4"}},{"id":2549468,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"Arsenault Kaitlyn Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-10-05T20:42:51.000Z","date":"2021-10-04","kind":"grant","acquired":true,"shares":1600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"10% of the Options shall vest on October 4, 2021 (the \"Vesting Start Date\") and the remaining 90% of the Options will vest in equal semi-annual installments over four annual periods."}],"balance_after":2000000,"derivative":{"exercise_price":0.09,"expiration_date":"2031-10-04","underlying":"Common Stock","underlying_shares":1600000},"source":{"system":"sec-edgar","filing":"0001516551-21-000014","document":"wf-form4_163348095684882.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655121000014/wf-form4_163348095684882.xml","form_type":"4"}}]}